EA200901065A1 - Ингибиторы pi 3-киназы и способы их применения - Google Patents
Ингибиторы pi 3-киназы и способы их примененияInfo
- Publication number
- EA200901065A1 EA200901065A1 EA200901065A EA200901065A EA200901065A1 EA 200901065 A1 EA200901065 A1 EA 200901065A1 EA 200901065 A EA200901065 A EA 200901065A EA 200901065 A EA200901065 A EA 200901065A EA 200901065 A1 EA200901065 A1 EA 200901065A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diseases
- alone
- pharmaceutically acceptable
- therapeutic agent
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
В заявке описаны ингибиторы фосфатидилинозит (PI) 3-киназы, их фармацевтически приемлемые соли и пролекарства; композиции этих новых соединений, по отдельности или в комбинации по меньшей мере с одним дополнительным терапевтическим средством, с фармацевтически приемлемым носителем; и применение этих новых соединений, по отдельности или в комбинации по меньшей мере с одним дополнительным терапевтическим средством, для профилактики или лечения заболеваний, характеризующихся аномальной активностью факторов роста, протеинсерин/треонинкиназ и фосфолипидкиназ, включая пролиферативные заболевания, воспалительные и обструктивные заболевания дыхательных путей, аллергические патологические состояния, аутоиммунные и сердечно-сосудистые заболевания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88846507P | 2007-02-06 | 2007-02-06 | |
PCT/US2008/053190 WO2008098058A1 (en) | 2007-02-06 | 2008-02-06 | Pi 3-kinase inhibitors and methods of their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200901065A1 true EA200901065A1 (ru) | 2010-02-26 |
Family
ID=39485187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200901065A EA200901065A1 (ru) | 2007-02-06 | 2008-02-06 | Ингибиторы pi 3-киназы и способы их применения |
Country Status (12)
Country | Link |
---|---|
US (1) | US8173647B2 (ru) |
EP (1) | EP2118087B1 (ru) |
JP (1) | JP2010518107A (ru) |
KR (1) | KR20090108124A (ru) |
CN (1) | CN101711241A (ru) |
AT (1) | ATE551334T1 (ru) |
AU (1) | AU2008213808B2 (ru) |
CA (1) | CA2675558A1 (ru) |
EA (1) | EA200901065A1 (ru) |
ES (1) | ES2381895T3 (ru) |
MX (1) | MX2009008341A (ru) |
WO (1) | WO2008098058A1 (ru) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
TW200908984A (en) * | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
EP2349275B1 (en) * | 2008-10-31 | 2017-03-08 | Novartis AG | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
WO2010068863A2 (en) * | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
NZ595372A (en) | 2009-03-27 | 2013-11-29 | Vetdc Inc | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
EP2451802A1 (en) | 2009-07-07 | 2012-05-16 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
WO2011008931A2 (en) * | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
KR101467858B1 (ko) | 2009-12-28 | 2014-12-02 | 재단법인 생물기술개발중심 | mTOR 및 PI3K 억제제로서의 신규 피리미딘 화합물 |
JP2013522215A (ja) | 2010-03-09 | 2013-06-13 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 組合わせ抗癌療法 |
GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
KR20130119928A (ko) | 2010-10-01 | 2013-11-01 | 노파르티스 아게 | 피리미딘 유도체의 제조 방법 |
JP2014500308A (ja) | 2010-12-21 | 2014-01-09 | ノバルティス アーゲー | Vps34阻害剤としてのビヘテロアリール化合物 |
AU2012225382B2 (en) * | 2011-03-09 | 2016-10-27 | Celgene Avilomics Research, Inc. | PI3 kinase inhibitors and uses thereof |
WO2012135160A1 (en) | 2011-03-28 | 2012-10-04 | Pathway Therapeutics Inc. | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases |
PE20141581A1 (es) | 2011-09-27 | 2014-11-14 | Novartis Ag | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante |
AP4055A (en) | 2011-12-22 | 2017-03-07 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
JP6381523B2 (ja) | 2012-05-16 | 2018-08-29 | ノバルティス アーゲー | Pi−3キナーゼ阻害剤の投与レジメン |
KR20160027219A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
WO2014022728A1 (en) | 2012-08-02 | 2014-02-06 | Endo Pharmaceuticals, Inc | Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer |
JP6183053B2 (ja) * | 2012-08-22 | 2017-08-23 | 宇部興産株式会社 | テトラヒドロピラニルピリミジン化合物の製造方法 |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
CN103012284A (zh) * | 2012-12-26 | 2013-04-03 | 无锡捷化医药科技有限公司 | 一种2-氨基-5-溴嘧啶类化合物的制备方法 |
WO2014110466A1 (en) * | 2013-01-12 | 2014-07-17 | Dawei Zhang | Pyridine compounds used as pi3 kinase inhibitors |
ES2665619T3 (es) | 2013-03-14 | 2018-04-26 | Novartis Ag | 3-Pirimidin-4-il-oxazolidin-2-onas como inhibidores de IDH mutante |
CN110003178B (zh) * | 2013-05-01 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 二杂芳基化合物及其用途 |
CN103483345B (zh) * | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
RU2019107011A (ru) | 2014-01-24 | 2019-04-08 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
CN105541792B (zh) * | 2014-10-22 | 2018-03-13 | 山东轩竹医药科技有限公司 | 多环类pi3k抑制剂 |
US10206910B2 (en) | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
MA40933A (fr) * | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
CN105294572A (zh) * | 2015-10-13 | 2016-02-03 | 安徽泓德化工技术有限公司 | 一甲氧基嘧啶胺的制备方法 |
CN109414415B (zh) * | 2016-05-18 | 2023-05-02 | 拓客股份有限公司 | 皮肤病变的治疗 |
SG11201809792TA (en) * | 2016-05-18 | 2018-12-28 | Piqur Therapeutics Ag | Treatment of neurological disorders |
AU2017275657B2 (en) | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
LT3571193T (lt) | 2017-01-23 | 2022-02-10 | Cadent Therapeutics, Inc. | Kalio kanalo moduliatoriai |
MX2019013862A (es) | 2017-05-23 | 2020-01-20 | Mei Pharma Inc | Terapia de combinacion. |
MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
CN109651341A (zh) * | 2017-10-11 | 2019-04-19 | 上海医药工业研究院 | 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用 |
EP3728230A1 (en) * | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
CN114213340B (zh) | 2022-02-22 | 2022-06-07 | 北京蓝晶微生物科技有限公司 | 2,4-二氨基嘧啶氧化物的制备方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
AT340933B (de) * | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
US4929726A (en) * | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
JP3145410B2 (ja) * | 1995-04-13 | 2001-03-12 | 大鵬薬品工業株式会社 | 新規な4,6−ジアリールピリミジン誘導体及びその塩 |
JP3734907B2 (ja) * | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
AU727013B2 (en) * | 1997-07-24 | 2000-11-30 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent comprising the same as effective component |
US6150362A (en) * | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
DK0930302T3 (da) * | 1998-01-16 | 2003-07-21 | Hoffmann La Roche | Benzosulfonderivater |
AU768201B2 (en) | 1999-01-22 | 2003-12-04 | Amgen, Inc. | Kinase inhibitors |
US6495558B1 (en) * | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
EP1274705A1 (en) | 2000-03-29 | 2003-01-15 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
WO2001083460A1 (fr) | 2000-04-28 | 2001-11-08 | Tanabe Seiyaku Co., Ltd. | Composes cycliques |
WO2002000647A1 (en) * | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU2001292670A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
BR0116411A (pt) | 2000-12-21 | 2003-11-11 | Vertex Pharma | Compostos de pirazol úteis como inibidores de proteìna cinase |
JP2004531571A (ja) * | 2001-05-25 | 2004-10-14 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン生産のインヒビターとしてのカルバメート及びオキサミド化合物 |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
US6603000B2 (en) * | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
AU2003218215A1 (en) * | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
DE60332433D1 (de) * | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
EP1485381B8 (en) * | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
WO2003078423A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
AU2003295776B2 (en) * | 2002-11-21 | 2011-05-12 | Novartis Vaccines And Diagnostics, Inc. | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
EP1608622A4 (en) | 2003-03-24 | 2009-04-01 | Merck & Co Inc | BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
CA2531490A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
AU2004257289A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
PE20050952A1 (es) * | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
EP1979325A1 (en) * | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CA2660758A1 (en) * | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
-
2008
- 2008-02-06 CA CA002675558A patent/CA2675558A1/en not_active Abandoned
- 2008-02-06 ES ES08729174T patent/ES2381895T3/es active Active
- 2008-02-06 KR KR1020097018520A patent/KR20090108124A/ko not_active Application Discontinuation
- 2008-02-06 AT AT08729174T patent/ATE551334T1/de active
- 2008-02-06 CN CN200880003210A patent/CN101711241A/zh active Pending
- 2008-02-06 AU AU2008213808A patent/AU2008213808B2/en not_active Ceased
- 2008-02-06 WO PCT/US2008/053190 patent/WO2008098058A1/en active Application Filing
- 2008-02-06 EP EP08729174A patent/EP2118087B1/en not_active Not-in-force
- 2008-02-06 EA EA200901065A patent/EA200901065A1/ru unknown
- 2008-02-06 US US12/449,286 patent/US8173647B2/en active Active
- 2008-02-06 JP JP2009549215A patent/JP2010518107A/ja active Pending
- 2008-02-06 MX MX2009008341A patent/MX2009008341A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010518107A (ja) | 2010-05-27 |
MX2009008341A (es) | 2009-08-12 |
WO2008098058A1 (en) | 2008-08-14 |
EP2118087B1 (en) | 2012-03-28 |
AU2008213808A1 (en) | 2008-08-14 |
CA2675558A1 (en) | 2008-08-14 |
US20100048547A1 (en) | 2010-02-25 |
CN101711241A (zh) | 2010-05-19 |
US8173647B2 (en) | 2012-05-08 |
ES2381895T3 (es) | 2012-06-01 |
EP2118087A1 (en) | 2009-11-18 |
KR20090108124A (ko) | 2009-10-14 |
ATE551334T1 (de) | 2012-04-15 |
AU2008213808A8 (en) | 2009-09-24 |
AU2008213808B2 (en) | 2011-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200901065A1 (ru) | Ингибиторы pi 3-киназы и способы их применения | |
MX2010000716A (es) | Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa. | |
JO2660B1 (en) | Pi-3 inhibitors and methods of use | |
MX2008010397A (es) | Inhibidores de pi-3 quinasa y metodos para su uso. | |
CY1118513T1 (el) | Αναστολεις πρωτεϊνικης κινασης (παραλλαγες), χρηση αυτων στη θεραπεια ογκολογικων νοσων και μια φαρμακευτικη συνθεση βασισμενη σε αυτους | |
GEP20125624B (en) | Pyridazine derivatives as smo inhibitors | |
BR112014004504A2 (pt) | "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase" | |
EA201170434A1 (ru) | Макроциклические ингибиторы сериновых протеаз гепатита с | |
MY185103A (en) | Bezylamine derivatives as inhibitors of plasma kallikrein | |
MY170656A (en) | Kinase inhibitors | |
DOP2013000243A (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
NZ598489A (en) | Combination therapy for treating proliferative diseases | |
MX2010007584A (es) | Inhibidores de proteina cinasa y uso de los mismos. | |
PA8821301A1 (es) | Inhibidores a base de hidroxamato de desacetilasas b | |
IL219644A0 (en) | Kinase inhibitors and methods of use thereof | |
ATE502935T1 (de) | C-met-proteinkinasehemmer | |
TNSN08531A1 (en) | Phenylacetic acid derivatives as cox - 2 inhibitors | |
SE0402591D0 (sv) | Novel use | |
TR201901937T4 (tr) | 8-metil-1-fenil-imidazol[1,5-a]pirazin bileşikleri. | |
TH131154B (th) | อนุพันธ์ยูเรียซึ่งเป็นสารยับยั้งไคเนสและการใช้อนุพันธ์ดังกล่าวทางการบำบัด |